Younger patients with intermediate or high-risk acute myeloid leukemia (AML) obtain overall survival benefit from the upfront use of hematopoietic cell transplantation (HCT). We queried the National Cancer Database to study 19,897 younger patients (18-60 years) with intermediate or high-risk AML reported between 2003-2012. Multivariable logistic regression analysis was performed to identify variables associated with the utilization of HCT. Approximately 18.5% of younger patients received HCT as a part of initial therapy. A lower rate of utilization of HCT was associated with receipt of care in a non-academic hospital, African American race, male sex, age group 50-60 years, Charlson comorbidity score of ≥1, uninsured status, Medicaid or Medicare insurance, and lower educational or income status. The use of HCT in younger patients varies based on non-biologic factors such as race, hospital type, insurance, educational, and income status. Socioeconomic and health system factors contribute to disparity in the uptake of HCT in the US.
Introduction
The use of allogeneic hematopoietic cell transplant (HCT) in initial management of acute myeloid leukemia (AML), particularly in younger patients with intermediate or highrisk AML, can reduce the risk of relapse, enhance long-term disease control and improve overall survival. The survival benefit has been demonstrated in a meta-analysis of 24 prospective clinical trials [1] . Consequently, the current National Comprehensive Cancer Network (NCCN) guidelines [2] and 2017 European Leukemia Net recommendations [3] for AML recommend the use of upfront HCT in first remission in younger patients with intermediate or high-risk AML. With the development of safer alternate donor sources such as haploidentical donors or cord blood, a suitable donor can be found for virtually all patients. However, studies have demonstrated a low rate of utilization of HCT, particularly in older patients [4, 5] but in patients with AML in general [6] in the US. This is in contrast to a much higher rate of utilization of HCT in the Netherlands [7] , and Sweden [8] .
Biologic factors such as inability to achieve optimal disease control, the presence of significant comorbidities and poor functional status may limit the use of HCT in some patients but does not explain lack of receipt of HCT in most younger patients in the US. Previously, Pidala et al. [9] demonstrated a variation in the rate of physician referral for HCT based on factors such as insurance, social support, and race. While Pidala and colleagues performed a survey to analyze physicians' referral patterns, identifying factors associated with the actual utilization of HCT in younger patients based on empirical data can be equally important to improve access to HCT. We hypothesized that socioeconomic and health system factors are important determinants of the uptake of HCT in real practice in the US. For this analysis, we used the National Cancer Database (NCDB) to analyze factors associated with the receipt of HCT among younger patients with AML. Our study focuses on a recent cohort of younger patients with AML and provides national trend information regarding the use of HCT. Understanding of potential socioeconomic barriers to HCT is necessary to improve appropriate access to HCT in the future.
Methods

Data source and patient selection
This retrospective study used de-identified data and was exempt from oversight by the institutional review board at the University of Nebraska Medical Center. Using a NCDB participant user file, we extracted patient-level data of adult patients aged 18-60 years, who were diagnosed with AML between the calendar year 2003-2012. NCDB is a joint program of the Commission on Cancer of the American College of Surgeons and the American Cancer Society and was established in the year 1989. NCDB collects data from more than 1500 accredited cancer programs and captures approximately 70% of new cancer diagnosis in the United States. Certified tumor registrars use standard data item and coding definitions for data gathering. Data undergo monitoring for integrity and quality assurance [10] .
The NCDB provided records of 31,565 younger patients with newly diagnosed AML between 2003-2012. Exclusion criteria included patients with good-risk AML or missing data on HCT status ( Supplementary Fig. 1 ). Patients with good-risk AML (i.e., acute promyelocytic leukemia and core-binding factor AML) were identified using the International Classification of Diseases for Oncology version 3 
Study endpoints and variables analyzed
Our primary objective was to identify non-biological factors associated with the use of HCT in the study population, controlling for biologic factors such as age and comorbidity.
Variables analyzed are listed in Table 1 and included patient demographics, comorbidity score, socioeconomic status, insurance status, receipt of HCT, and facility type).
The burden of comorbidities is summarized by Charlson Comorbidity Scores of 0, 1, or ≥2. The aggregate percent of the population without a high school degree residing in the zip code of the patient, as determined by census data of the year 2000, is utilized to determine educational status.
Income status is also determined using the census data available for the zip code of the patient.
The street address of the reporting facility and the center of the patient's zip code of residence are used to calculate distance traveled to receive cancer care [11] . Facilities were classified in this study into academic and non-academic centers. Based on the definitions provided by Commission on Cancer [12] , academic centers are large NCI-designated cancer centers or have the availability of postgraduate medical education in at least four program areas. Comprehensive community cancer programs, community cancer programs, and other facilities were categorized as nonacademic centers. Most non-academic centers do not provide HCT services.
Statistical analysis SAS 9.4 (SAS Institute, Cary, NC) software was used for all analyses. Frequency and percentage were provided for different variables stratified by HCT status. The association between HCT status and all variables was determined using Chi-square test for univariable analysis, and subsequently multivariable logistic regression model. Odds ratio (OR) and 95% confidence interval (CI) were reported in the final model. A p-value <0.05 was used to determine statistical significance.
Results
A total of 19,897 younger patients with intermediate or high-risk AML were included in the study (Supplementary  Table 1 for histology). Of the studied population, 18.5% (n = 3683) underwent HCT as a part of initial therapy or consolidation (Supplementary Table 2 for types of HCT). The study population had a median age of 49 years (range 18-60), and consisted of predominantly white (82.2%), male (50.9%), and those with Charlson comorbidity score of 0 (82.7%). Treatment facility included academic centers (63.3%) and facilities in an urban location (98.2%). The 1-month and 3-month mortality were 5% and 12% among patients treated in academic centers, as compared to 8% and 15% among those treated in non-academic centers, respectively ( Supplementary Fig. 2) .
In a univariable analysis, the receipt of HCT was higher among patients aged 18-49 years, compared to those between the age of 50-60 years (20.3% vs. 16 18 .4%), receipt of first course treatment in an academic vs. non-academic center (23.9% vs. 9.1%), higher educational (p < 0.0001), income (p < 0.0001), and insurance status (p < 0.0001). Importantly, patients with private (22.4%) and other government insurance (18.9%) had a higher likelihood of receiving HCT. Patients who traveled longer distance to receive therapy (p < 0.0001) and those initiating therapy at a longer time from diagnosis (p < 0.0001) had a higher probability of undergoing HCT.
In a multivariable analysis, patients treated at a nonacademic center, African Americans, uninsured, Medicaid, and Medicare patients demonstrated a lower probability of receipt of HCT (Table 2 ). Other factors that predicted a lower receipt of HCT included age 50-60 years as compared to 18-49 years, lower educational and income status, and higher Charlson comorbidity score. Females, patients who traveled longer distance and those initiating therapy at a longer time from diagnosis had a higher likelihood of receiving HCT.
Discussion
Despite survival benefits associated with the use of HCT in intermediate and high-risk AML in younger patients, this large NCDB study demonstrated a low rate of utilization of HCT in recent years, consistent with general findings of prior studies conducted in the US [4] [5] [6] . The use of HCT was particularly low in patients aged 50-60 years and those with higher Charlson comorbidity score, highlighting the impact of biological factors such as age and comorbidities on the use of HCT. Indeed the presence of significant comorbidities, development of chemotherapy-related toxicities or poor functional status and early mortality can be important appropriate contraindications to HCT [13] , especially in the 50-60 age group. However, in a study by Mawad et al. [13] [7] . The rate of utilization of HCT is also much higher in Sweden [8] and Denmark [14] . Hence, biological factors alone cannot fully explain the discrepancy in the use of HCT in our study.
We hypothesized that socioeconomic and health system factors are important determinants of the use of HCT in real practice in the US. In a multivariable analysis, our study identified a threefold lower likelihood of receiving HCT among patients receiving initial care at non-academic centers, highlighting a significant impact of facility type on utilization of HCT. Although this study did not allow analysis of the underlying reason for such difference, this is not explained by rural vs. urban locations of the facility, which were largely balanced between HCT vs. non-HCT groups. The 3-month mortality was 12% among patients treated in academic centers, as compared to 15% among those treated in non-academic centers. This difference is much smaller than the difference in the receipt of HCT between academic and non-academic centers (23.9% vs. 9.1%), so difference in early mortality does not fully explain the higher rates of HCT among patients treated in academic centers. Some of the potential reasons may include lack of HCT services in non-academic centers, inadequate, or delayed referral to transplant centers or differences in patient characteristics based on the facility type. Among racial groups, African Americans were almost twofold less likely to undergo HCT, compared to whites. Patients from communities with lower educational and income status were less likely to receive HCT. Insurance status was an important determinant of the likelihood of receiving HCT. The use of HCT was low among uninsured patients and Medicare/Medicaid patients, compared to patients with private insurance. The association of private insurance coverage with higher rates of HCT is largely consistent with our prior study [15] . These important results highlight the significant impact of nonbiologic factors on the receipt of HCT and cancer care disparity. The receipt of HCT was higher in patients with a delay in initiation of therapy and those traveling a longer distance to receive care. Similar findings were noted in our study of older patients as well [16] . The nature of this study did not allow us to explore the reasons for these findings. We assume that a delay in initiation of therapy may be reflective of an indolent leukemia biology that permitted patients to proceed to HCT with lower risk of early mortality and progression of leukemia. A longer distance to the treating facility may be a surrogate marker of better functional status or receipt of care in academic centers, or larger centers with HCT services. Our prior NCDB analysis has demonstrated that patients traveled longer to receive care for AML in academic centers [17] .
Prior studies performed in other countries have demonstrated a variation in the use of HCT (Table 3 ). Whereas almost half of patients aged 18-60 years underwent HCT in the Netherlands (during 2007-2012) [7] , Sweden (during 1997-2006) [8] , and Denmark (during 2000-2014) [14] , a much lower percentage of patients underwent HCT in the UK (about 12% during 1998-2007) [18] . In the Sweden [8] and Denmark [14] studies, two-third of HCT were performed in patients in the first complete remission. These studies, however, differed significantly in terms of the time period of the study, focus of the study, age group of the study participants, among other factors. While most of the study calculated the rate of utilization of HCT, the major focus was on the overall treatment practices and outcomes of AML. Only the UK study [18] focused on determining the factors associated with the use of HCT, however, this study did not separate the analysis between younger (18-60 years) and older (above 60 years) patients, was unable to adjust for the cytogenetic risk group, and may not have captured minor comorbidities. Despite these limitations, increasing age (within the age interval of 18-60 years) was an important determinant of the receipt of HCT [7, 8, 18] . The Denmark study [14] demonstrated a lower use of HCT in first complete remission among patients with lower educational status. However, in this country with universal health-care system, income status did not influence the receipt of HCT. The UK study [18] demonstrated a lower rate of HCT utilization among patients from lower socioeconomic status, as measured by the Townsend Score (calculated based on unemployment, car ownership, home ownership, and overcrowding) [18] . The UK study did not evaluate the impact of educational status. Taken together with our study, factors such as educational status, income [7] 46-55% [17] , referral to a transplant center [9] , patients' understanding of the complexity of HCT processes, and physicians' recommendations to undergo HCT. This retrospective study did not have information about molecular markers frequently tested in AML, functional status of patients, remission status after initial therapy or at the time of HCT and volume of HCT performed in various facilities. We were also not able to explore the reasons why many patients did not undergo HCT. These are important areas for future research to try to understand the causes of health disparities. Given the large size of the study population, some small differences in the two comparison groups were also statistically significant but may not be clinically significant. Education and income status were estimated from the census data available for the zip code of the patient. Despite such limitations, this study utilized a large national database from recent years, demonstrated a low utilization of HCT in younger patients with AML and identified the impact of a number of non-biological factors on the receipt of HCT in real-world practice in the US.
The utilization of HCT needs to increase in eligible younger patients. Early referral of all potentially eligible patients to a transplant center is perhaps the single most important intervention to improve access to HCT. Strong collaboration and partnership between transplant physicians in academic centers and community oncologists are crucial for improving referrals. Multidisciplinary management of comorbidities can increase the use of HCT among some patients with comorbidities. Further research is necessary to understand how other racial and educational factors affect the receipt of HCT. Some of the potential strategies to overcome racial and educational barriers may include frequent discussions about the risk-benefit analysis of HCT taking into consideration the educational and cultural background of the patients, and providing opportunities for patients to meet prior transplant recipients particularly those who share educational and racial background with the patients. Increasing diversity in health-care workforce and enhancing cultural competence among members of a transplant team can also strengthen the ability of a transplant team to better understand patients' perspective and tailor patient counseling.
In conclusion, the use of HCT in younger patients is overall low in the US and varies based on non-biologic factors such as race, hospital type, insurance, educational and income status. Socioeconomic and health system factors contribute to disparity in the use of HCT, and should be addressed to improve utilization of HCT.
